Skip to main content
Top
Published in: Modern Rheumatology 2/2010

01-04-2010 | Original Article

Investigation of pathological and clinical features of lupus nephritis in 73 autopsied cases with systemic lupus erythematosus

Authors: Takayuki Kon, Ken Yamaji, Kaoru Sugimoto, Michihiro Ogasawara, Kazuo Kenpe, Hitoshi Ogasawara, Kwang-Seok Yang, Hiroshi Tsuda, Toshiharu Matsumoto, Hiroshi Hashimoto, Yoshinari Takasaki

Published in: Modern Rheumatology | Issue 2/2010

Login to get access

Abstract

The aims of this study were to analyze the clinical and pathological features of lupus nephritis (LN) and examine the association between these features and pathological condition, treatment, and prognosis. Of the 177 systemic lupus erythematosus patients who died while receiving inpatient care at Juntendo University Hospital between 1960 and 2001, we investigated the clinical features, treatment, and pathological features of 73 of these who underwent pathological autopsy and had a clear medical history. We divided these cases into two groups, i.e., those up to 1979 (Group A) and those during and after 1980 (Group B) in order to investigate changes in tendencies by age. We also divided the cases into three groups by time interval between diagnosis and death to investigate long-term prognosis. Uremia was the direct cause of death in 38.9% of cases in Group A and only 10.8% of cases in Group B. Pathological features showed a tendency to change to a sclerotic lesion as the duration of the disorder became longer. Uremia attributable to LN was the direct cause of death in relatively fewer cases, although it is still found in the majority of LN cases and remains a problem requiring stringent management. The treatment of sclerotic lesions may be an issue that needs further attention.
Literature
1.
go back to reference Arao T, Fujiki T, Kosumi H, Hatono C, Numata T. 4 autopsy cases of systemic lupus erythematosus, especially on lupus nephritis. Nippon Hifuka Gakkai Zasshi. 1961;71:524–33.PubMed Arao T, Fujiki T, Kosumi H, Hatono C, Numata T. 4 autopsy cases of systemic lupus erythematosus, especially on lupus nephritis. Nippon Hifuka Gakkai Zasshi. 1961;71:524–33.PubMed
2.
go back to reference Grishman E, Gerber MA, Churg J. Patterns of renal injury in systemic lupus erythematosus: light and immunofluorescence microscopic observations. Am J Kidney Dis. 1982;2[Suppl 1]:135–41.PubMed Grishman E, Gerber MA, Churg J. Patterns of renal injury in systemic lupus erythematosus: light and immunofluorescence microscopic observations. Am J Kidney Dis. 1982;2[Suppl 1]:135–41.PubMed
3.
go back to reference Grishman E, Venkataseshan VS. Vascular lesions in lupus nephritis. Mod Pathol. 1988;1(3):235–41.PubMed Grishman E, Venkataseshan VS. Vascular lesions in lupus nephritis. Mod Pathol. 1988;1(3):235–41.PubMed
4.
go back to reference Tan Eng M, Cohen Alan S, Fries James F, Masi Alfonse T, McShane Dennis J, Rothfield Naomi F, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271–7.CrossRefPubMed Tan Eng M, Cohen Alan S, Fries James F, Masi Alfonse T, McShane Dennis J, Rothfield Naomi F, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271–7.CrossRefPubMed
5.
go back to reference Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.CrossRefPubMed Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.CrossRefPubMed
6.
go back to reference Austin HA 3rd, Muenz LR, Joyce KM, Antonovych TT, Balow JE. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int. 1984;25:689–95.CrossRefPubMed Austin HA 3rd, Muenz LR, Joyce KM, Antonovych TT, Balow JE. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int. 1984;25:689–95.CrossRefPubMed
7.
go back to reference Weening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004;65:521–30.CrossRefPubMed Weening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004;65:521–30.CrossRefPubMed
8.
go back to reference Churg J, Sobin LH. Renal disease: classification and atlas of glomerular disease. Tokyo: Igaku-Shoin; 1982. p. 127–31. Churg J, Sobin LH. Renal disease: classification and atlas of glomerular disease. Tokyo: Igaku-Shoin; 1982. p. 127–31.
9.
go back to reference Churg J, Bernstein J, Glassok RJ. Renal disease: classification and atlas of glomerular disease. 2nd ed. New York: Igaku-Shoin; 1995. p. 151–6. Churg J, Bernstein J, Glassok RJ. Renal disease: classification and atlas of glomerular disease. 2nd ed. New York: Igaku-Shoin; 1995. p. 151–6.
10.
go back to reference Merrel M, Shulman LE. Determination of prognosis in chronic disease, illustrated by systemic lupus erythematosus. J Chronic Dis. 1955;1:12–32.CrossRef Merrel M, Shulman LE. Determination of prognosis in chronic disease, illustrated by systemic lupus erythematosus. J Chronic Dis. 1955;1:12–32.CrossRef
11.
go back to reference Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestation in a cohort of 1000 patients. Medicine. 2003;82:299–308.CrossRefPubMed Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestation in a cohort of 1000 patients. Medicine. 2003;82:299–308.CrossRefPubMed
12.
go back to reference Mok CC, Lee KW, Ho CT, Lau CS, Wong RW. A prospective study of survival and prognostic indicators of systemic lupus erythematosus in a southern Chinese population. Rheumatology (Oxford). 2000;39:399–406.CrossRef Mok CC, Lee KW, Ho CT, Lau CS, Wong RW. A prospective study of survival and prognostic indicators of systemic lupus erythematosus in a southern Chinese population. Rheumatology (Oxford). 2000;39:399–406.CrossRef
13.
go back to reference Mok CC, Wong RW, Lau CS. Lupus nephritis in southern Chinese patients: clinicopathologic findings and long-term outcome. Am J Kidney Dis. 1999;34:315–23.CrossRefPubMed Mok CC, Wong RW, Lau CS. Lupus nephritis in southern Chinese patients: clinicopathologic findings and long-term outcome. Am J Kidney Dis. 1999;34:315–23.CrossRefPubMed
14.
go back to reference Bono L, Cameron JS, Hicks JA. The very long-term prognosis and complications of lupus nephritis and its treatment. QJM. 1999;92:211–8.CrossRefPubMed Bono L, Cameron JS, Hicks JA. The very long-term prognosis and complications of lupus nephritis and its treatment. QJM. 1999;92:211–8.CrossRefPubMed
15.
go back to reference Mok CC, Mak A, Chu WP, To CH, Wong SN. Long-term survival of southern Chinese patients with systemic lupus erythematosus. Medicine. 2005;84:218–24.CrossRefPubMed Mok CC, Mak A, Chu WP, To CH, Wong SN. Long-term survival of southern Chinese patients with systemic lupus erythematosus. Medicine. 2005;84:218–24.CrossRefPubMed
16.
go back to reference Kang I, Park SH. Infectious complications in SLE after immunosuppressive therapies. Curr Opin Rheumatol. 2003;15:528–34.CrossRefPubMed Kang I, Park SH. Infectious complications in SLE after immunosuppressive therapies. Curr Opin Rheumatol. 2003;15:528–34.CrossRefPubMed
17.
go back to reference Fiehn C, Hajiar Y, Mueller K, Waldherr R, Ho AD, Andrassy K. Improved clinical outcome of lupus nephritis during the past decade: importance of early diagnosis and treatment. Ann Rheum Dis. 2003;62:435–9.CrossRefPubMed Fiehn C, Hajiar Y, Mueller K, Waldherr R, Ho AD, Andrassy K. Improved clinical outcome of lupus nephritis during the past decade: importance of early diagnosis and treatment. Ann Rheum Dis. 2003;62:435–9.CrossRefPubMed
18.
go back to reference Nagasawa T. Collagen disease and dialysis—overview. Jpn J Clin Dial. 1995;11:917–22. Nagasawa T. Collagen disease and dialysis—overview. Jpn J Clin Dial. 1995;11:917–22.
19.
go back to reference Doria A, Iaccarino L, Ghirardello A, Zampieri S, Arienti S, Sarzi-Puttini P, et al. Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med. 2006;119:1497–9.CrossRef Doria A, Iaccarino L, Ghirardello A, Zampieri S, Arienti S, Sarzi-Puttini P, et al. Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med. 2006;119:1497–9.CrossRef
20.
go back to reference Bernatsky S, Clarke A, Ramsey-Goldman R. Malignancy and systemic lupus erythematosus. Curr Rheumatol Rep. 2002;4:351–8.CrossRefPubMed Bernatsky S, Clarke A, Ramsey-Goldman R. Malignancy and systemic lupus erythematosus. Curr Rheumatol Rep. 2002;4:351–8.CrossRefPubMed
21.
go back to reference Abu-Shakra M, Ehrenfeld M, Shoenfeld Y. Systemic lupus erythematosus and cancer: associated or not? Lupus. 2002;11:137–44.CrossRefPubMed Abu-Shakra M, Ehrenfeld M, Shoenfeld Y. Systemic lupus erythematosus and cancer: associated or not? Lupus. 2002;11:137–44.CrossRefPubMed
22.
go back to reference Najafi CC, Korbet SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J. Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis. Kidney Int. 2001;59:2156–63.PubMed Najafi CC, Korbet SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J. Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis. Kidney Int. 2001;59:2156–63.PubMed
23.
go back to reference Contreras G, Lenz O, Pardo V, Borja E, Cely C, Iqbal K, et al. Outcomes in African American s and Hispanics with lupus nephritis. Kidney Int. 2006;69:1846–51.CrossRefPubMed Contreras G, Lenz O, Pardo V, Borja E, Cely C, Iqbal K, et al. Outcomes in African American s and Hispanics with lupus nephritis. Kidney Int. 2006;69:1846–51.CrossRefPubMed
24.
go back to reference Terai C, Koseki Y, Uesato M, Moriguchi M. Lupus nephritis. Intern Med. 1999;83:78–81. Terai C, Koseki Y, Uesato M, Moriguchi M. Lupus nephritis. Intern Med. 1999;83:78–81.
25.
go back to reference Gonzalez-Crespo MR, Lopez-Fernandez JI, Usera G, Poveda MJ, Gomez-Reino JJ. Outcome of silent lupus nephritis. Semin Arthritis Rheum. 1996;26:468–76.CrossRefPubMed Gonzalez-Crespo MR, Lopez-Fernandez JI, Usera G, Poveda MJ, Gomez-Reino JJ. Outcome of silent lupus nephritis. Semin Arthritis Rheum. 1996;26:468–76.CrossRefPubMed
26.
go back to reference Zabaleta-Lanz M, Vargas-Arenas RE, Tapanes F, Daboin I, Atahualpa Pinto J, Bianco NE. Silent nephritis in systemic lupus erythematosus. Lupus. 2003;12:26–30.CrossRefPubMed Zabaleta-Lanz M, Vargas-Arenas RE, Tapanes F, Daboin I, Atahualpa Pinto J, Bianco NE. Silent nephritis in systemic lupus erythematosus. Lupus. 2003;12:26–30.CrossRefPubMed
27.
go back to reference Valeri A, Radhakrishnan J, Estes D, D’Agati V, Kopelman R, Pernis A, et al. Intravenous pulse cyclophosphamide treatment of severe lupus nephritis: a prospective five-year study. Clin Nephrol. 1994;42:71–8.PubMed Valeri A, Radhakrishnan J, Estes D, D’Agati V, Kopelman R, Pernis A, et al. Intravenous pulse cyclophosphamide treatment of severe lupus nephritis: a prospective five-year study. Clin Nephrol. 1994;42:71–8.PubMed
28.
go back to reference Kunis CL, Kiss B, Williams G, et al. Intravenous “pulse” cyclophosphamide therapy of crescentic glomerulonephritis. Clin Nephrol. 1992;37(1):1–7.PubMed Kunis CL, Kiss B, Williams G, et al. Intravenous “pulse” cyclophosphamide therapy of crescentic glomerulonephritis. Clin Nephrol. 1992;37(1):1–7.PubMed
29.
go back to reference Tse KC, Li FK, Tang CS, Lai KN, Chan TM. Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinurea. Lupus. 2005;14:947–52.CrossRefPubMed Tse KC, Li FK, Tang CS, Lai KN, Chan TM. Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinurea. Lupus. 2005;14:947–52.CrossRefPubMed
30.
go back to reference Honma M, Ichikawa Y, Akizuki M, Kashiwazaki S, Kondo H, Hashimoto H, et al. Double blind trial of pulse methylprednisolone versus conventional oral prednisolone in lupus nephritis. Ryumachi. 1994;34(3):616–27.PubMed Honma M, Ichikawa Y, Akizuki M, Kashiwazaki S, Kondo H, Hashimoto H, et al. Double blind trial of pulse methylprednisolone versus conventional oral prednisolone in lupus nephritis. Ryumachi. 1994;34(3):616–27.PubMed
31.
go back to reference Gourley MF, Austin HA 3rd, Scott D, Yarboro CH, Vaughan EM, Muir J, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled tiral. Ann Intern Med. 1996;125(7):549–57.PubMed Gourley MF, Austin HA 3rd, Scott D, Yarboro CH, Vaughan EM, Muir J, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled tiral. Ann Intern Med. 1996;125(7):549–57.PubMed
32.
go back to reference Sesso R, Monteiro M, Sato E, Kirsztajn G, Silva L, Ajzen H. A controlled trial of pulse cyclophosphamide versus pulse methylprednisolone in severe lupus nephritis. Lupus. 1994;3(2):107–12.CrossRefPubMed Sesso R, Monteiro M, Sato E, Kirsztajn G, Silva L, Ajzen H. A controlled trial of pulse cyclophosphamide versus pulse methylprednisolone in severe lupus nephritis. Lupus. 1994;3(2):107–12.CrossRefPubMed
33.
go back to reference Radharkrishnan J, Kunis CL, D’Agati V, Appel GB. Cyclosporin treatment of lupus membranous nephropathy. Clin Nephrol. 1994;42:147–54. Radharkrishnan J, Kunis CL, D’Agati V, Appel GB. Cyclosporin treatment of lupus membranous nephropathy. Clin Nephrol. 1994;42:147–54.
34.
go back to reference Rihova Z, Vankova Z, Maixnerova D, Dostal C, Jancova E, Honsova E, et al. Treatment of lupus nephritis with cyclosporine—an outcome analysis. Kidney Blood Press Res. 2007;30(2):124–8.CrossRefPubMed Rihova Z, Vankova Z, Maixnerova D, Dostal C, Jancova E, Honsova E, et al. Treatment of lupus nephritis with cyclosporine—an outcome analysis. Kidney Blood Press Res. 2007;30(2):124–8.CrossRefPubMed
35.
go back to reference Jonsdottir T, Gunnarsson I, Risselada A, Henriksson EW, Klareskog L, van Vollenhoven RF. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann Rheum Dis. 2008;67(3):330–4.CrossRefPubMed Jonsdottir T, Gunnarsson I, Risselada A, Henriksson EW, Klareskog L, van Vollenhoven RF. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann Rheum Dis. 2008;67(3):330–4.CrossRefPubMed
36.
go back to reference Mok CC, Tong KH, To CH, Siu YP, Au TC. Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study. Kidney Int. 2005;68:813–7.CrossRefPubMed Mok CC, Tong KH, To CH, Siu YP, Au TC. Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study. Kidney Int. 2005;68:813–7.CrossRefPubMed
37.
go back to reference Cordeiro AC, Isenberg DA. Novel therapies in lupus—focus on nephritis. Acta Reumatol Port. 2008;33(2):157–69.PubMed Cordeiro AC, Isenberg DA. Novel therapies in lupus—focus on nephritis. Acta Reumatol Port. 2008;33(2):157–69.PubMed
38.
go back to reference Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J Rheumatol. 1995;22:1259–64.PubMed Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J Rheumatol. 1995;22:1259–64.PubMed
39.
go back to reference Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestation in a cohort of 1000 patients. Medicine (Baltimore). 2003;82:299–308.CrossRef Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestation in a cohort of 1000 patients. Medicine (Baltimore). 2003;82:299–308.CrossRef
40.
go back to reference Doria A, Iaccarino L, Ghirardello A, Zampieri S, Arienti S, Sarzi-Puttini P, et al. Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med. 2006;119:700–6.CrossRefPubMed Doria A, Iaccarino L, Ghirardello A, Zampieri S, Arienti S, Sarzi-Puttini P, et al. Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med. 2006;119:700–6.CrossRefPubMed
Metadata
Title
Investigation of pathological and clinical features of lupus nephritis in 73 autopsied cases with systemic lupus erythematosus
Authors
Takayuki Kon
Ken Yamaji
Kaoru Sugimoto
Michihiro Ogasawara
Kazuo Kenpe
Hitoshi Ogasawara
Kwang-Seok Yang
Hiroshi Tsuda
Toshiharu Matsumoto
Hiroshi Hashimoto
Yoshinari Takasaki
Publication date
01-04-2010
Publisher
Springer Japan
Published in
Modern Rheumatology / Issue 2/2010
Print ISSN: 1439-7595
Electronic ISSN: 1439-7609
DOI
https://doi.org/10.1007/s10165-009-0260-3

Other articles of this Issue 2/2010

Modern Rheumatology 2/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.